NCT04800822 2024-10-22PF-07284892 in Participants With Advanced Solid TumorsPfizerPhase 1 Terminated53 enrolled
NCT02857270 2022-11-22A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerEli Lilly and CompanyPhase 1 Completed210 enrolled